About this trial
Bronchiectasis is a chronic respiratory disease clinically characterized by recurrent pulmonary exacerbations, chronic cough, and sputum production, and is associated with an increase in the airway-artery ratio and permanent airway dilatation. It is recognized as the third most common chronic respiratory disease after chronic obstructive pulmonary disease (COPD) and asthma. In the International Classification of Diseases and Related Health Problems (ICD-10), it has its own diagnostic code (J47.9).
In bronchiectasis, mucociliary clearance is impaired due to bronchial dilatation, and the insufficient clearance of bacteria and mucus from the respiratory tract leads to persistent infection, inflammation, and further airway damage. Progressive airway damage results in impaired lung function, worsening of symptoms, and, ultimately, respiratory failure and death. It can represent the final pathway of various infectious, allergic, inflammatory, genetic, and degenerative disorders, making it one of the most complex and heterogeneous syndromes. Some patients present with daily symptoms, while others remain asymptomatic except during exacerbations. The most common symptom is chronic cough caused by purulent or mucopurulent sputum. Other symptoms include dyspnea, pleuritic chest pain, wheezing, fatigue, and weight loss. Fever, however, is not a common finding and differs from pneumonia.
The most frequently used classification system categorizes bronchiectasis into varicose, cylindrical, and saccular (cystic) types. In the most severe form, the saccular type, the bronchi lose their structural integrity completely, forming cystic structures filled with secretions. The mildest form is cylindrical, in which the bronchi have thick, straight walls. In the varicose type, localized narrowings are observed. Diagnosis is made following history and physical examination, with high-resolution computed tomography (HRCT) being the most sensitive and specific method, along with sputum culture and chest radiography.
The goals of bronchiectasis treatment are to manage symptoms, prevent complications, and improve quality of life. Both pharmacological and patient-managed interventions are commonly applied. Pharmacological treatments include antibiotics, bronchodilators, and corticosteroids, which are generally administered via inhalation. Patient-managed interventions require active participation and behavioral modification. Within published guidelines, airway clearance techniques are widely described under pulmonary rehabilitation (PR), but there is no consensus regarding PR itself. For individuals with reduced exercise tolerance, participation in PR and engagement in physical activity are recommended. However, research has shown that referral rates to PR are often low, and exercise and physical activity are not consistently prescribed.
Within PR, techniques such as the active cycle of breathing techniques (ACBT), postural drainage, thoracic expansion exercises, and various airway clearance methods are applied, with inspiratory muscle training (IMT) forming an important component. Functional inspiratory muscle training (FIMT) is an IMT program developed by considering not only the ventilatory roles of the respiratory muscles but also their non-respiratory functions. FIMT integrates inspiratory muscle training with core stabilization and postural control exercises. The rhythmic co-contractions of the muscles in the core region support trunk stability and provide the basis for movement. In the first stage of the program, participants receive IMT, and subsequently, core stabilization training and dynamic trunk activation exercises are incorporated into the intervention.
A review of the literature reveals that no studies have investigated the effectiveness of FIMT in adults with bronchiectasis. In our study, we aim to evaluate the effects of FIMT, applied in addition to home-based chest physiotherapy, on pulmonary function, diaphragm thickness, balance, core stability, functional capacity, physical activity, posture, and quality of life in adults with bronchiectasis. Furthermore, we aim to compare these outcomes with those of IMT applied alongside home-based chest physiotherapy. We believe that this approach will contribute to the development of treatment strategies in clinical practice and help address existing gaps in the literature.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age between 18 and 30 years
Diagnosed with bronchiectasis
Clinically stable
Able to cooperate
Disqualifiers
History of acute exacerbation and/or hospitalization within the past 4 weeks
Change in medical treatment within the past month
Known diagnosed conditions affecting balance (visual, auditory, vestibular, or musculoskeletal disorders)
Participation in a supervised physiotherapy rehabilitation program within the past 6 months
Trial design
Parallel
Treatments tested in this trial
Functional Inspiratory Muscle Training (FIMT)
Other interventionParticipants will begin with Inspiratory Muscle Training (IMT) at 50% of maximal inspiratory pressure (MIP) for 4 weeks. Training will be performed once a week face-to-face, while adherence will be monitored on other days via WhatsApp. During each face-to-face session, MIP will be reassessed and training loads adjusted. Participants will perform 30 dynamic inspiratory efforts twice daily. In the following 4 weeks, Functional Inspiratory Muscle Training (FIMT) will be applied: once face-to-face, twice online under physiotherapist supervision, and twice unsupervised IMT. FIMT exercises will be performed with the POWERbreathe Classic Light Resistance device, consisting of 10 breaths lasting 15-30 seconds in 2 sets. Each session will include warm-up (diaphragmatic breathing and trunk stretches), loading (core stabilization exercises), and cool-down (trunk stretches). IMT intensity will be adjusted weekly using MIP measurement
Inspiratory Muscle Training (IMT)
Other interventionParticipants will perform IMT daily for 8 weeks. Training will be conducted once a week face-to-face, while on other days adherence will be monitored via WhatsApp. The group will complete 30 dynamic inspiratory efforts twice daily. The POWERbreathe Classic Light Resistance device (PowerBreathe, IMT Technologies Ltd, Birmingham, UK) will be used to strengthen the diaphragm and chest wall muscles by breathing against a set pressure load. Training intensity will be set at 50% of maximal inspiratory pressure (MIP). After 10-15 consecutive breaths, participants will perform 3-4 recovery breaths before continuing. IMT intensity will be re-adjusted weekly during face-to-face sessions using MIP measurements to maintain 50% loading.
Treatment groups
Trial outcomes
Primary outcomes
Forced Expiratory Volume in 1 Second (FEV1)
FEV1 will be assessed using a spirometer (Cosmed Pony FX) under ATS/ERS standards. The measurement will be recorded in liters and as a percentage of the predicted normal value.
Forced Vital Capacity (FVC)
Forced Vital Capacity (FVC) will be measured using a portable spirometer (Cosmed Pony FX, Italy) following ATS/ERS guidelines. Results will be recorded in liters and as a percentage of the predicted value.
FEV1/FVC Ratio
The ratio of FEV1 to FVC (FEV1/FVC) will be calculated to assess airway obstruction. The values will be expressed as a percentage. All procedures will be carried out with standardized spirometry protocols (ATS/ERS) using single-use mouthpieces and filters.
Peak Expiratory Flow (PEF)
PEF will be measured as part of the pulmonary function test using a spirometer. Values will be expressed in liters per second (L/s) and as a percentage of the predicted value. Infection control procedures will include the use of disposable mouthpieces and filters as per device guidelines.
Secondary outcomes
Physical Activity (Accelerometer Assessment)
Physical activity will be objectively assessed using a triaxial accelerometer (Actigraph wGT3X+). Participants will be instructed to wear the device for 7 consecutive days, removing it only during water-based activities. A minimum of 4 valid days (including 1 weekend day) with at least 10 hours of wear time per day will be required for data inclusion. The device records activity counts, intensity, and energy expenditure across three axes, with vector magnitude calculated. Data will be analyzed using ActiLife6 software. Outcomes will include sedentary time, total physical activity, light physical activity, and moderate-to-vigorous physical activity (MVPA). Compliance with the physical activity guideline of at least 60 minutes of MVPA per day will also be evaluated (yes/no).
Posture Assessment
Posture will be assessed using the validated PostureScreen® Mobile application. Three standardized photographs (anterior, right lateral, and left lateral) will be taken with the smartphone camera using a vertical axis as reference. Anatomical reference points will be marked, and deviations from the midline will be analyzed.
Quality of Life (Leicester Cough Questionnaire - LCQ)
Quality of life will be assessed using the Leicester Cough Questionnaire (LCQ), a 19-item, 7-point Likert-type scale with three subdomains: physical (8 items), psychological (7 items), and social (4 items). Lower scores indicate greater impairment from cough, while higher scores indicate less impact. The Turkish version of the scale has been validated and found reliable.
Patient Satisfaction (Telemedicine Satisfaction Questionnaire - TSQ)
Patient satisfaction with remote rehabilitation will be assessed using the Telemedicine Satisfaction Questionnaire (TSQ). This validated 14-item scale uses a 5-point Likert format, with total scores ranging from 14 to 70. Higher scores indicate greater satisfaction with telemedicine-based rehabilitation services.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Elif Kabasakal
Lead sponsor
Istinye University
Sponsor institution